这项研究描述了一系列新型取代的1-(氨基甲基)-2-(芳基乙酰基)-1,2,3,4-四氢异喹啉的合成,并讨论了它们对阿片受体的结合亲和力与它们的结构活性关系(SAR)。抗伤害感受力作为生物活性的指标。在异喹啉核的5位上引入羟基取代基产生了一种化合物40,其效力比抗伤害感受的小鼠模型中先前公开的未取代类似物39强2倍。对5-取代基的QSAR分析清楚地表明,抗伤害感受活性与取代基的亲脂性成反比。与未取代的异喹啉39相比,本文所述的取代化合物对κ阿片受体的选择性较低。5-羟基取代的化合物59对kappa阿片受体具有很高的亲和力(Ki kappa = 0.09 nM),Ki mu / Ki kappa之比仅为5。但是,多元线性回归分析表明,抗伤害性与对μ阿片样物质受体的亲和力。另一方面,对κ阿片受体的结合亲和力与抗伤害感受活性之间的相关性具有统计学意义。
这项研究描述了一系列新型取代的1-(氨基甲基)-2-(芳基乙酰基)-1,2,3,4-四氢异喹啉的合成,并讨论了它们对阿片受体的结合亲和力与它们的结构活性关系(SAR)。抗伤害感受力作为生物活性的指标。在异喹啉核的5位上引入羟基取代基产生了一种化合物40,其效力比抗伤害感受的小鼠模型中先前公开的未取代类似物39强2倍。对5-取代基的QSAR分析清楚地表明,抗伤害感受活性与取代基的亲脂性成反比。与未取代的异喹啉39相比,本文所述的取代化合物对κ阿片受体的选择性较低。5-羟基取代的化合物59对kappa阿片受体具有很高的亲和力(Ki kappa = 0.09 nM),Ki mu / Ki kappa之比仅为5。但是,多元线性回归分析表明,抗伤害性与对μ阿片样物质受体的亲和力。另一方面,对κ阿片受体的结合亲和力与抗伤害感受活性之间的相关性具有统计学意义。
[EN] 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS DE L'ACIDE CARBOXYLIQUE PHÉNOXYCHROMANE SUBSTITUÉS EN 6
申请人:ARRAY BIOPHARMA INC
公开号:WO2009158426A1
公开(公告)日:2009-12-30
Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.
It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect.
The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use.
A compound of the formula (I) having a binding activity to the cannabinoid type 2 receptor:
1
wherein R
1
is optionally substituted heterocyclic group or the like; R
2
and R
2
each is independently hydrogen or the like; m is an integer of 0 to 2; A is optionally substituted aromatic carbocyclic group or the like.
The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use.